Trial Profile
A Phase 2 proof of concept program on Female Sexual Arousal Disorder and Hypoactive Sexual Desire Disorder
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Feb 2016
Price :
$35
*
At a glance
- Drugs Lasofoxifene (Primary)
- Indications Decreased libido
- Focus Proof of concept; Therapeutic Use
- 12 Feb 2016 New trial record
- 10 Feb 2016 Results from this trial will be presented at the annual meeting of the International Society for the Study of Women's Sexual Health (ISSWSH), according to a Sermonix Pharmaceuticals media release.